Evidence network for deaths_(OS)

3CheckMate 017, 2015 CheckMate 057, 2015 CheckMate 078, 20192KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016 KEYNOTE-010 (P: 2mg/kg), 20163POPLAR, 2016 OAK (all population), 2016 OAK (PDL1 TC 1/2/3), 20161ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 20202JAVELIN Lung 200 (PDL1 >1%), 2018 JAVELIN Lung 200 (all population), 20181CAURAL (EXPLORATORY), 20192KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016 KEYNOTE-010 (P:10 mg/kg), 20161ARCTIC (DT ; study B ; PDL1<25%), 20201CodeBreaK 200, 2022docetaxelStandard of Care (SoC)osimertinibno control (uncontrolled study)nivolumab alonepembrolizumab (2mg/kg)atezolizumab alonedurvalumab aloneavelumab alonedurvalumab plus osimertinibpembrolizumab (10mg/kg)durvalumab plus tremelimumabTislelizumabsotorasibtrametinib plus dabrafenibdirect evidencenetwork meta-analysis
T vs. C docetaxelStandard of Care (SoC)osimertinibno control (uncontrolled study)nivolumab alonepembrolizumab (2mg/kg)atezolizumab alonedurvalumab aloneavelumab alonedurvalumab plus osimertinibpembrolizumab (10mg/kg)durvalumab plus tremelimumabTislelizumabsotorasibtrametinib plus dabrafenib
docetaxel---NANANANANANANANANANANANANANA
Standard of Care (SoC)NA---NANANANANANANANANANANANANA
osimertinibNANA---NANANANANANANANANANANANA
no control (uncontrolled study)NANANA---NANANANANANANANANANANA
nivolumab aloneNANANANA---NANANANANANANANANANA
pembrolizumab (2mg/kg)NANANANANA---NANANANANANANANANA
atezolizumab aloneNANANANANANA---NANANANANANANANA
durvalumab aloneNANANANANANANA---NANANANANANANA
avelumab aloneNANANANANANANANA---NANANANANANA
durvalumab plus osimertinibNANANANANANANANANA---NANANANANA
pembrolizumab (10mg/kg)NANANANANANANANANANA---NANANANA
durvalumab plus tremelimumabNANANANANANANANANANANA---NANANA
TislelizumabNANANANANANANANANANANANA---NANA
sotorasibNANANANANANANANANANANANANA---NA
trametinib plus dabrafenibNANANANANANANANANANANANANANA---

pathologies: 197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169 - treatments: 425,562 result logic